CDC20 overexpression predicts a poor prognosis for patients with colorectal cancer

Abstract

BackgroundThe cell division cycle 20 homolog (CDC20) is an essential cofactor of the anaphase-promoting complex (APC/C). CDC20 overexpression has been detected in many types of human cancers; however, its clinical role in colorectal cancer remains unknown.MethodsWestern blotting and immunohistochemistry were used to compare CDC20 expression in adjacent non-cancerous, cancerous and liver metastatic tissues as well as in colon cancer cell lines and normal colon epithelial cell lines. Additionally, the correlation of CDC20 expression with patient clinical parameters and its diagnostic value were statistically analyzed.ResultsCDC20 was overexpressed in colon cancer cell lines/primary cancer tissues compared with normal colon epithelial cell lines/adjacent noncancerous tissue samples. Interestingly, CDC20 expression was further increased in metastatic liver tissues. CDC20 protein expression was significantly correlated with clinical stage (P = 0.008), N classification (P = 0.020), M classification (P = 0.013) and pathologic differentiation (P = 0.008). Patients with higher CDC20 expression had a shorter overall survival than those with lower CDC20 expression. Univariate and multivariate analyses indicated that CDC20 expression was an independent prognostic factor (P < 0.001).ConclusionCDC20 may serve as a potential prognostic biomarker of human colorectal cancer.

A comprehensive analysis of CDC20 overexpression in common malignant tumors from multiple organs: its correlation with tumor grade and stage

“…CDC20 expression was detected in the nuclei and/or cytoplasm of the tumor cells as shown in previous studies [23,25,26,36,38,39]. CDC20 overexpression was detected in 55.7 % while low CDC20 expression was found in 44.3 % of all examined malignant tumors.…”

“…Positive CDC20 expression was observed in the breast, colon, endometrium, head and neck, kidney, lung, ovary, pancreas, prostate, and testis. Previous studies reported positive CDC20 expression in the normal/non-neoplastic epithelial cells of Graph 1 CDC20 immunohistochemical expression in normal/non-neoplastic tissues and primary malignant tumors from multiple organs the colon, stomach, head and neck, and pancreas (23,26,27,36), while others reported that CDC20 expression was negative in normal/non-neoplastic epithelial cells of the bladder, breast, cervix, liver, and lung [24,25,[37][38][39]. Our comprehensive study corroborated and expanded these observations as we found negative CDC20 expression in normal/non-neoplastic tissues from the bladder, cervix, liver, stomach, and thyroid.…”

“…The scoring system was adjusted from previously published studies [26]. The percent of positive cells was scored as 0=≤10 %, 1=>10 to ≤25 %, 2=>25 to ≤50 %, 3=>50 to ≤75 %, and 4=>75 %.…”

“…High CDC20 expression has been reported in several human cancers and its expression has been linked to poor prognosis in pancreatic [23], lung [24], bladder [25], colon [26], and oral squamous cell carcinomas [27].…”

CDC20 with malignant progression and poor prognosis of astrocytoma revealed by analysis on gene expression

“…APC activation is required for anaphase initiation and mitosis exit [10]. In addition, it was recently found that CDC20 overexpressed in many types of human cancers, including human nonsmall cell lung cancer, pancreatic cancer, gastric cancer, colorectal cancer, glioma, breast cancer, and oral cancer [10][11][12][13][14][15][16]. It suggests that CDC20 maybe play an important role in the mechanism of the occurrence and development of glioma.…”